Drugs / lopinavir/ritonavir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00143689 | Apr 2002 → Feb 2008 | HIV infectious disease | University of British Columbia | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2012-03-06 | Merck Sharp & Dohme LLC | Results Results from Investigational Studies with VICTRELIS™ (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1 merck.com ↗
In this study, concomitant administration of VICTRELIS with ritonavir (Norvir ® ) in combination with atazanavir (Reyataz ® ) or darunavir (Prezista ® ), or with lopinavir/ritonavir (Kaletra ® ) resulted in reduced exposures of the HIV medicines and VICTRELIS. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-02-27 | AbbVie | AbbVie Statement on Coronavirus and lopinavir/ritonavir abbvie.com ↗ |
| 2012-03-06 | Merck Sharp & Dohme LLC | Results from Investigational Studies with VICTRELIS™ (boceprevir) Presented at the Conference on Retroviruses and Opportunistic Infections to Understand Potential Use in Patients Coinfected with Chronic Hepatitis C and HIV-1 merck.com ↗ |
| 2006-08-17 | Vertex Pharmaceuticals Incorporated | Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet vrtx.com ↗ |
| 2006-05-16 | Vertex Pharmaceuticals Incorporated | GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV vrtx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lopinavir/ritonavir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00143689 ↗ |
| Known as | Kaletra | “lopinavir/ritonavir (Kaletra) and nevirapine (Viramune) twice a day;” NCT00143689 ↗ |